DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients

Liu, Xinyan; Fu, Jinming; Bi, Haoran; Ge, Anqi; Xia, Tingting; Liu, Yupeng; Sun, Hongru; Li, Dapeng; Zhao, Yashuang

doi:10.1186/s12885-019-6436-0

BMC Cancer

Table 5 Subgroup analysis on the association between methylation and OS ^a

From: DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients

Symbol	Subgroup	Univariate Cox		Multivariate Cox		Propensity score-1		Propensity score-2
Symbol	Subgroup	Crude HR (95%CI)	P value	Adjusted HR ^b (95%CI)	P value	Adjusted HR ^b (95%CI)	P value	Adjusted HR ^c (95%CI)	P value
SFRP2	Age
	< 45 years-old	0.150 (0.020–1.148)	0.068	0.021 (0.001–0.348)	0.007	0.126 (0.016–1.025)	0.053	0.161 (0.021–1.263)	0.082
	≥ 45 years-old	0.346 (0.160–0.748)	0.007	0.414 (0.188–0.911)	0.028	0.479 (0.221–1.035)	0.061	0.537 (0.246–1.173)	0.119
	Gender
	Male	0.373 (0.149–0.935)	0.035	0.357 (0.135–0.945)	0.038	0.471 (0.186–1.197)	0.113	0.551 (0.213–1.427)	0.219
	Female	0.214 (0.066–0.698)	0.011	0.311 (0.091–1.056)	0.061	0.328 (0.098–1.102)	0.071	0.291 (0.085–1.005)	0.051
	Tumor location
	Colon	0.177 (0.043–0.733)	0.017	0.120 (0.027–0.527)	0.005	0.203 (0.049–0.843)	0.028	0.215 (0.052–0.899)	0.035
	Rectum	0.413 (0.178–0.960)	0.040	0.570 (0.237–1.366)	0.207	0.673 (0.291–1.557)	0.355	0.722 (0.308–1.695)	0.455
	TNM Staging
	I-II	0.372 (0.132–1.048)	0.061	0.375 (0.126–1.119)	0.079	0.442 (0.156–1.254)	0.125	0.428 (0.150–1.221)	0.112
	III-IV	0.311 (0.113–0.859)	0.024	0.280 (0.097–0.809)	0.019	0.374 (0.133–1.048)	0.061	0.452 (0.160–1.272)	0.132
	Postoperative chemotherapy
	No	0.249 (0.078–0.797)	0.019	0.284 (0.085–0.945)	0.040	0.381 (0.117–1.239)	0.109	0.365 (0.111–1.203)	0.098
	Yes	0.360 (0.142–0.910)	0.031	0.392 (0.150–1.026)	0.056	0.448 (0.177–1.130)	0.089	0.535 (0.207–1.384)	0.197
SFRP1+ SFRP2	Age
	< 45 years-old	0.150 (0.020–1.148)	0.068	0.021 (0.001–0.348)	0.007	0.119 (0.014–1.025)	0.053	0.151 (0.019–1.225)	0.077
	≥ 45 years-old	0.334 (0.155–0.720)	0.005	0.399 (0.181–0.879)	0.023	0.463 (0.212–1.008)	0.052	0.523 (0.238–1.152)	0.108
	Gender
	Male	0.356 (0.143–0.886)	0.026	0.339 (0.130–0.884)	0.027	0.448 (0.179–1.119)	0.086	0.526 (0.206–1.343)	0.179
	Female	0.214 (0.066–0.698)	0.011	0.311 (0.091–1.056)	0.061	0.328 (0.098–1.103)	0.072	0.304 (0.090–1.022)	0.054
	Tumor location
	Colon	0.177 (0.043–0.733)	0.017	0.120 (0.027–0.527)	0.005	0.200 (0.048–0.832)	0.027	0.213 (0.051–0.890)	0.034
	Rectum	0.397 (0.172–0.918)	0.031	0.546 (0.227–1.312)	0.176	0.656 (0.278–1.551)	0.337	0.708 (0.297–1.690)	0.437
	TNM Staging
	I-II	0.372 (0.132–1.048)	0.061	0.375 (0.126–1.119)	0.079	0.445 (0.157–1.260)	0.127	0.434 (0.152–1.237)	0.118
	III-IV	0.295 (0.108–0.809)	0.018	0.263 (0.092–0.751)	0.013	0.352 (0.127–0.970)	0.044	0.419 (0.147–1.193)	0.103
	Postoperative chemotherapy
	No	0.249 (0.078–0.797)	0.019	0.284 (0.085–0.945)	0.040	0.381 (0.117–1.239)	0.109	0.360 (0.109–1.191)	0.094
	Yes	0.343 (0.137–0.861)	0.023	0.372 (0.144–0.961)	0.041	0.426 (0.168–1.076)	0.071	0.517 (0.200–1.332)	0.172

^aAll HR values were referenced by hypomethylation
^bControlling for the variables which included age, gender, CEA, CA19–9, TNM staging, pathological classification, differentiation degree and postoperative radiotherapy
^cControlling for the variables which included age, gender, CEA, CA19–9, multiple polyps, tumor location, TNM staging, pathological classification, histologic classification, differentiation degree, postoperative chemotherapy and postoperative radiotherapy

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com